Can Express Scripts Holding Co. Beat Expectations Again?

Despite a long run of success and market-leading share, the Street seems skeptical that Express Scripts can find more savings

Apr 7, 2014 at 9:00AM

Pharmacy benefit management company, or PBM, Express Scripts (NASDAQ:ESRX) has done quite well for investors in the past, but Wall Street is less confident about the future. Analysts are skeptical that, with the large advances already made in the shift to generics, Express Scripts can leverage formulary design, producer discounts, mail delivery and other drivers to continue generating double-digit free cash flow growth.

That skepticism could work in investors' favor, though, as Express Scripts looks like one of the relatively few meaningfully undervalued large health care companies.

The biggest pure-play left
Having acquired Medco in 2012, Express Scripts is far and away the largest PBM, handling close to one-third of prescriptions. At that size, Express Scripts is about four times the size of the next-largest pure-play Catamaran (NASDAQ:CTRX), though retail-PBM hybrid CVS Caremark (NYSE:CVS) claims around 20% of scripts and is a very competitive player in the space. Express Scripts also competes with managed care companies that run their PBMs, most notably UnitedHealth Group's (NYSE:UNH) OptumRx, and newcomers like Costco which launched its own PBM in 2013.

Express Scripts manages pharmacy benefits for close to 100 million lives, it's reasonably well diversified across employers, and health plans (with WellPoint as its largest customer). Size is important, as Express Scripts' scale gives it important leverage when negotiating with drug manufacturers on price, as well as retail pharmacy chains.

Generics fading as a tailwind
The past decade was a big one for generic drug manufacturers like Teva and Mylan, as well as PBMs like Express Scripts, as billions of dollars of branded drugs went off patent. As Express Scripts, CVS Caremark, and Catamaran were able to shift more and more prescriptions to generics, they were able to continue to post solid profit growth despite ongoing pricing pressure from clients.

That generic substitution tailwind, which likely contributed at least half of Express Scripts' earnings growth over the past decade, is probably not going to be repeated over the next decade. There aren't nearly as many high-value branded drugs going off patent, generic substitution rates are already high, and new drugs like PCSK9 inhibitors for cholesterol are going to hit the market.

Specialty pharmacies and formularies will fill at least some of the gap
Express Scripts still has levers to pull to save money for employers and managed care plan operators on pharmaceuticals. Specialty pharmaceuticals, including biologicals for inflammatory conditions like rheumatoid arthritis, oncology drugs, and drugs for MS, make up only a single-digit percentage of script volume, but around one-third of spending.

With CVS Caremark, Express Scripts is one of the largest specialty pharmacy operators, with significant operations on both the pharmacy and fulfillment sides. Better managing these costs is a significant value-add opportunity and Express Scripts stands to become a major beneficiary if and when biosimilars (essentially generic versions of biological drugs like Humira or Lantus) reach the market in significant volumes.

Controlling the formulary is another way Express Scripts can cut costs. In essence, this is a process where Express Scripts chooses one version of a drug (or removes a particular version) and includes/excludes it from plan members. In practice, this means that Express Scripts can obtain very competitive bids for included drugs and/or exclude particularly expensive drugs. But it does run the risk of alienating and angering members (patients with chronic conditions don't like to change a medication that has been working, even if the replacement is supposed to be basically identical).

A relentless drive toward lower costs
I have no particular expectations for Express Scripts to earn significant revenue growth in the coming years. Smaller rivals are growing their capacity, while larger rivals like CVS Caremark are looking to integrate the drug supply chain. Rivals like UnitedHealth's OptumRx are going to push hard to grow (as scale brings savings) and large customers are more than willing to play PBMs off each other for better deals.

I do expect, though, that Express Scripts will find additional drivers for improved savings and margins. The company's scale in specialty drugs is significant and the potential price benefits from biosimilar substitution are large. Management also believes there is more to do with expense synergies from the Medco deal and conversion to a mail-order pharmacy. The penetration here is just under 30% and management believes it can hit 40% in the medium-term and perhaps as high as 70% down the line.

All told, I'm looking for revenue growth of around 3% from Express Scripts, with ongoing margin improvements leading to a free cash flow growth rate close to double that. Discounted back, I believe these shares are worth around $85 today.

Bottom line
CVS Caremark, UnitedHealth, and Catamaran are not trivial rivals, and Express Scripts no longer has the benefit of substantial conversions to generics to help grow its profits. Even so, the company's considerable scale and opportunity to leverage that scale with manufacturer discounts, formulary control, and savings in specialty pharmaceuticals should allow for additional margin leverage. On that basis, Express Scripts appears to offer meaningful value at these levels.

6 stock picks poised for incredible growth
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.

Stephen D. Simpson, CFA has no position in any stocks mentioned. The Motley Fool recommends Catamaran, CVS Caremark, Express Scripts, UnitedHealth Group, and WellPoint. The Motley Fool owns shares of Catamaran, Express Scripts, and WellPoint. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers